Benzinga | Nov 15, 2021 11:09AM EST

CymaBay Therapeutics Long-term Open Label Study Finds Treatment With Seladelpar For Two Years Improves Key Liver Biomarkers In Patients With PBC

* Study results presented at The Liver Meeting(r) 2021 demonstrated continued reductions in biomarkers of cholestasis and hepatocellular injury over two years

* Seladelpar generally appeared safe with low rates of discontinuation and no liver-related serious adverse events over two years of treatment

* A second clinical presentation found seladelpar treatment in patients with compensated cirrhosis and evidence of portal hypertension resulted in improvements in biomarkers of cholestasis and hepatocellular injury

* These results will also be presented during a post-AASLD Key Opinion Leader (KOL) webinar on seladelpar in PBC on Monday, Nov. 15